Secondary graft-versus-host disease (GVHD) prophylaxis with oral proteasome inhibitor ixazomib is associated with low incidence of recurrent, late acute and chronic GVHD and facilitated calcineurin inhibitor taper within the first year post allogeneic stem cell transplantation Meeting Abstract


Authors: Rodriguez, N.; Lee, J.; Flynn, L.; Murray, F.; Devlin, S.; Izquierdo, C. S.; Cho, C.; Dahi, P. B.; Giralt, S. A.; Sauter, C. S.; Perales, M. A.; Ponce, D. M.
Abstract Title: Secondary graft-versus-host disease (GVHD) prophylaxis with oral proteasome inhibitor ixazomib is associated with low incidence of recurrent, late acute and chronic GVHD and facilitated calcineurin inhibitor taper within the first year post allogeneic stem cell transplantation
Meeting Title: 62nd Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 136
Issue: Suppl. 1
Meeting Dates: 2020 Dec 5-8
Meeting Location: Virtual
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2020-11-05
Language: English
ACCESSION: WOS:000607547204041
DOI: 10.1182/blood-2020-139666
PROVIDER: wos
Notes: Meeting Abstract: 41 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sergio Andres Giralt
    1050 Giralt
  2. Craig Steven Sauter
    334 Sauter
  3. Doris Ponce
    254 Ponce
  4. Miguel-Angel Perales
    913 Perales
  5. Sean McCarthy Devlin
    601 Devlin
  6. Christina Cho
    134 Cho
  7. Parastoo Bahrami Dahi
    294 Dahi
  8. Lisa Flynn
    7 Flynn
  9. Jasme Lee
    31 Lee
  10. Fiona Murray
    2 Murray